Rentschler names Benedikt von Braunmuehl as CEO; Catalent grabs David McErlane from Lonza as biologics lead
Benedikt von Braunmuehl has been revealed as Rentschler Biopharma’s new CEO. Meanwhile, Catalent also announced that David McErlane is the CDMO’s new group president of its biologic segment.
Von Braunmuehl, the former CEO of HMNC Brain Health, replaced Frank Mathias, who shifted to Oxford Biomedica in February after seven years at Rentschler. Tuesday marks von Braunmuehl’s first day on the job.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.